StreetAlpha.app
Home › Stocks › AARD

Aardvark Therapeutics, Inc. (AARD)

$1.18
▼ −6.35%
LAST CLOSE · NOV 17

Aardvark Therapeutics is a San Diego biopharmaceutical company developing oral medicines that aim to reduce hunger in metabolic conditions. It last closed at $1.18 on Nov 17, down 6.35% on the day. The average 12-month price target from 2 analysts is $6.00 (+408.5% from the last close), with a high of $10.00 and a low of $2.00.

AI Auto Pilots
Is AARD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$72.8M
EPS (diluted)
−$3.33
Free cash flow
−$66.8M
Valuation
Market cap
$25.8M
21.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$60.3M
At Sep 30
Shareholder equity
$57.6M
Shares outstanding
21.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$20.6M−$20.6MFY2024FY2025: −$57.6M−$57.6MFY2025

From AARD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated AARD in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 408.5% upside

Based on 2 analysts who set a price target on AARD in the past 90 days. The average target is $6.00, with a high of $10.00 and a low of $2.00, compared with the last close of $1.18.

Low $2.00Avg $6.00High $10.00
Blue marker: last close $1.18
Highest target$10.00
Average target$6.00
Lowest target$2.00
Latest rating changes
Jones TradingMaintained
Oct 27Buy$10
HC Wainwright & Co.Target lowered
Oct 26Hold$4 → $2
HC Wainwright & Co.Target lowered
Oct 19Hold$6 → $4
HC Wainwright & Co.Reiterated
Jul 20Hold$6
Morgan StanleyDowngrade
May 15Sell$7 → $3
DateFirmActionRatingPrice target
Oct 27Jones TradingMaintainedBuy$10
Oct 26HC Wainwright & Co.Target loweredHold$4 → $2
Oct 19HC Wainwright & Co.Target loweredHold$6 → $4
Jul 20HC Wainwright & Co.ReiteratedHold$6
May 15Morgan StanleyDowngradeSell$7 → $3
Loading…

Technical Analysis

AARD · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 36% below its 20 day and 205% below its 50 day average. It is 368% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), oversold. The nearest support is the swing low (Nov 6) at $1.09, and the nearest resistance the Pivot at $1.22.

Short trendBearish
Long trendBearish
MomentumFading
StretchOversold
VolatilityHigh, 28.8%/day
Key levels
$16.6052 week high+1306.8%
$5.53200 day average+368.6%
$4.96100 day average+320.3%
$3.5950 day average+204.2%
$1.68Swing high (Nov 11)+42.4%
$1.6020 day average+35.6%
$1.34Pivot R1+13.6%
$1.22Pivot+3.4%
$1.18Last close
$1.09Swing low (Nov 6)−7.6%
$1.06Pivot S1−10.2%
$0.9352 week low−21.2%
Indicators
RSI (14)29.80Oversold below 30Oversold
MACD-0.69Above its signal lineBullish
Stochastic28.3Middle of its rangeNeutral
ADX (14)42.5Strong downtrend
Williams %R-84.7Oversold below −80, overbought above −20Oversold
CCI (20)-51.3Oversold below −100, overbought above 100Neutral
Rate of change−4.1%Change over 10 sessionsBearish
ATR (14)$0.34Typical daily range, 28.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AARD

What happened before

See how AARD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in AARD in the last 90 days.

Loading…

See today’s whale options flow across the market →

AARD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●35 buying vs 37 selling
  • ●Held by funds -0.0 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7672+5.6%
In funds' top 10110.0%
Held by funds43.6%43.6%−0.0 pts
New / increased14 / 2119 / 21−12.5%
Reduced / sold out27 / 1023 / 24−21.3%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AARD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AARD is in one of them and how their past AARD trades turned out.

AARD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AARD in an article yet. Here's the latest on the wider market.

About Aardvark Therapeutics

Aardvark Therapeutics is a biopharmaceutical company based in San Diego, California, that develops small molecule medicines aimed at reducing hunger. Its work centers on compounds that act on bitter taste receptors in the gut, which are designed to prompt the body to release its own appetite-related hormones. Its lead candidate, ARD-101, is an oral drug being studied for hyperphagia, an extreme hunger condition associated with Prader-Willi syndrome. The company has no approved products yet and aims to serve patients with metabolic conditions and the clinicians who treat them.

Headquarters
San Diego, CA